Spots Global Cancer Trial Database for metastatic prostate adenocarcinoma
Every month we try and update this database with for metastatic prostate adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | NCT03317392 | Castration-Resi... Metastatic Pros... Stage IVB Prost... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Magnetic Resona... Olaparib Quality-of-Life... Radium Ra 223 D... | 18 Years - | National Cancer Institute (NCI) | |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | NCT04754425 | Castration-Resi... Castration-Resi... Metastatic Mali... Metastatic Pros... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Biopsy Biospecimen Col... Erdafitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | NCT02099864 | Castration-Resi... Metastatic Mali... Metastatic Mali... Metastatic Pros... Recurrent Prost... Stage III Prost... Stage IV Prosta... | Enzalutamide | 18 Years - | OHSU Knight Cancer Institute | |
| A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers | NCT01261754 | Prostate Cancer | 99mTc MIP 1404 99mTc MIP 1405 | 21 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | NCT05733351 | Castration-Sens... Metastatic Pros... Stage IVB Prost... | Abiraterone Biospecimen Col... Bone Scan Computed Tomogr... Docetaxel Enzalutamide FDG-Positron Em... Magnetic Resona... PSMA PET Scan Vudalimab | 18 Years - | Emory University | |
| Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | NCT05054296 | Biochemically R... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Educational Int... Exercise Interv... FitBit Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones | NCT04616547 | Castration-Resi... Metastatic Mali... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Questionnaire A... Tin Sn 117m Pen... | 18 Years - | National Cancer Institute (NCI) | |
| Evaluation of PSMA Antagonist Produced by Two Different Methods | NCT04685811 | Metastatic Pros... | 68Ga-PSMA-gener... | 21 Years - 100 Years | Weill Medical College of Cornell University | |
| Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT04781374 | Metastatic Pros... Castration-resi... Prostate Cancer Prostate Cancer... | Neratinib | 18 Years - | Beth Israel Deaconess Medical Center | |
| Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients | NCT05156372 | Prostate Cancer... Castrate Resist... Metastatic Pros... Metastatic Pros... | High Intensity ... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Tumor Molecular Profiling in Patients With Prostate Cancer | NCT05573789 | Prostate Cancer Metastatic Pros... | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT05479578 | Castration-Resi... Metastatic Pros... Stage IVB Prost... | Cyclophosphamid... Dexamethasone | 18 Years - | University of California, Davis | |
| Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | NCT05054296 | Biochemically R... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Educational Int... Exercise Interv... FitBit Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Tumor Molecular Profiling in Patients With Prostate Cancer | NCT05573789 | Prostate Cancer Metastatic Pros... | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Tumor Molecular Profiling in Patients With Prostate Cancer | NCT05573789 | Prostate Cancer Metastatic Pros... | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Measuring Oncological Value of Exercise and Statin | NCT05796973 | Prostate Cancer Breast Cancer Kidney Cancer Ovarian Cancer Metastatic Brea... Metastatic Kidn... Metastatic Rena... Metastatic Rena... Metastatic Pros... Metastatic Pros... Metastatic Ovar... Metastatic Ovar... | Guided physical... Atorvastatin Independent exe... | 18 Years - 99 Years | Tampere University Hospital | |
| A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers | NCT01261754 | Prostate Cancer | 99mTc MIP 1404 99mTc MIP 1405 | 21 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT04704505 | Prostate Adenoc... Metastatic Pros... Castration-resi... | radium-223 Bipolar Androge... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | NCT04734730 | Castration-Sens... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Bicalutamide Degarelix Goserelin Aceta... Leuprolide Acet... Prednisone Questionnaire A... Talazoparib | 18 Years - | City of Hope Medical Center | |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial | NCT05168618 | Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Atezolizumab Cabozantinib S-... | 18 Years - | University of Utah | |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | NCT04734730 | Castration-Sens... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Bicalutamide Degarelix Goserelin Aceta... Leuprolide Acet... Prednisone Questionnaire A... Talazoparib | 18 Years - | City of Hope Medical Center | |
| Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT04704505 | Prostate Adenoc... Metastatic Pros... Castration-resi... | radium-223 Bipolar Androge... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment | NCT04190446 | Metastatic Pros... Oligometastatic... Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Intensity-Modul... Proton Beam Rad... Quality-of-Life... Questionnaire A... Computed Tomogr... Magnetic Resona... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT05445609 | Metastatic Pros... Stage IV Prosta... | VLP-encapsulate... Nivolumab | 18 Years - | Emory University | |
| Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | NCT03902951 | Metastatic Pros... Prostate Adenoc... Recurrent Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Leuprolide Acet... Quality-of-Life... Questionnaire A... Stereotactic Bo... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment | NCT04190446 | Metastatic Pros... Oligometastatic... Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Intensity-Modul... Proton Beam Rad... Quality-of-Life... Questionnaire A... Computed Tomogr... Magnetic Resona... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment | NCT04190446 | Metastatic Pros... Oligometastatic... Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Intensity-Modul... Proton Beam Rad... Quality-of-Life... Questionnaire A... Computed Tomogr... Magnetic Resona... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | NCT05113537 | Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Metastatic Cast... Metastatic Cast... | Abemaciclib Lutetium Lu 177... | 18 Years - | University of California, San Francisco | |
| Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients | NCT05156372 | Prostate Cancer... Castrate Resist... Metastatic Pros... Metastatic Pros... | High Intensity ... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | NCT05113537 | Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Metastatic Cast... Metastatic Cast... | Abemaciclib Lutetium Lu 177... | 18 Years - | University of California, San Francisco | |
| Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | NCT06039371 | Castration-Resi... Metastatic Pros... Stage IVB Prost... | Biopsy Biospecimen Col... Bone Scan Carboplatin Computed Tomogr... Etoposide Quality-of-Life... Questionnaire A... Testosterone Cy... | 18 Years - | University of Washington |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
